Rheumatoid arthritis/undifferentiated arthritis Musculoskeletal Diseases Rheumatoid arthritis
Conditions
Interventions
Baseline:
Data at baseline for all enrolled patients who sign informed consent:
1. Age
2. Gender
3. Years of education
4. Smoking (never, previous, current daily smoker)
5. Presumed diagnosis
6. Time
Sponsors
Diakonhjemmet Hospital (Norway)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Group 1: 1. Patients of both genders 2. Aged 18 - 75 years 3. Patients with arthritis in at least 2 peripheral joints of less than 16 weeks duration (onset of arthritis is defined as the time when at least one joint became swollen) Group 2: 1. Patients of both genders 2. Aged 18 - 75 years with RA according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria 3. Patients with arthritis of less than 12 months duration (onset of arthritis is defined as the time when at least one joint became swollen) Group 3: Patients of both genders aged 18 - 75 years with any arthritis (including monoarthritis) of less than 12 months duration with presence of positive anti-CCP and/or rheumatoid factor. Onset of arthritis is defined as the time when at least one joint became swollen. Group 4: Patients in group 2 and 3 who start treatment with a disease modifying anti-rheumatic drug (DMARD)
Exclusion criteria
Exclusion criteria: Patients with the following reasons for joint swelling will be excluded from follow-up: 1. Osteoarthritis 2. Trauma 3. Mechanical joint lesion (e.g. meniscus lesion) 4. Gout 5. Pseudogout 6. Septic arthritis 7. Acute sarcoid arthropathy If any of these conditions are diagnosed during the course of the study, patients will be excluded from further follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured yearly throughout the study: 1. Development of rheumatoid arthritis or other specific inflammatory arthritic disease according to established classification criteria 2. Development of erosive arthritis | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at study end: 1. Achievement of stable remission of disease activity 2. Health status 3. Quality of life/utility 4. Indirect costs | — |
Countries
Norway
Outcome results
None listed